Pharmaceuticals

Global Personalized Medicine Biomarkers Market 2025–2029: Competitive Insights and Opportunities

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Personalized Medicine Biomarkers Industry By The Forecast Year 2029?

The personalized medicine biomarkers market has seen rapid expansion in recent years. Its size is expected to increase from $22.85 billion in 2024 to $26.73 billion in 2025, progressing at a compound annual growth rate (CAGR) of 17.0%. This historical development can be attributed to the increasing prevalence of chronic diseases, rising adoption of companion diagnostics, growing investment in biomarker research, rising focus on early diagnosis and preventive healthcare, and regulatory support for biomarker-based therapies.

The market for personalized medicine biomarkers is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $50.33 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.1%. Factors contributing to this growth throughout the forecast period include the expanding utility in precision oncology, rising need for targeted therapies, increased emphasis on early disease detection, escalating consumer preference for personalized methods, and favorable government policies along with financial support. Key trends emerging during this forecast timeframe encompass the implementation of multi-omics strategies for biomarker identification, the advancement of liquid biopsy-derived biomarkers, the growing application of digital biomarkers, the integration of AI and machine learning in the discovery of biomarkers, and the broader incorporation of real-world evidence in biomarker validation.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

What Are The Main Drivers Boosting The Personalized Medicine Biomarkers Industry’s Expansion?

The increasing incidence of chronic illnesses is anticipated to drive the expansion of the personalized medicine biomarkers market in the future. These conditions are defined as enduring health issues that evolve gradually and persist for at least a year, necessitating continuous healthcare or restricting everyday functions. This rise in chronic disease prevalence stems from poor lifestyle decisions, inadequate nutrition, insufficient physical exercise, and elevated stress levels. Personalized medicine biomarkers facilitate the customization of treatments for chronic ailments through the identification of effective therapies, forecasting disease advancement, and reducing negative side effects, all informed by individual genetic and molecular profiles. As an illustration, in February 2024, the World Health Organization (WHO), a health authority located in Switzerland, projected that new cancer diagnoses would exceed 35 million by 2050, marking a 77% surge from the approximate 20 million cases reported in 2022. Consequently, the escalating occurrence of chronic diseases is fueling the expansion of the personalized medicine biomarkers market.

How Is The Personalized Medicine Biomarkers Market Segmented?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

What Are The Major Trends Driving The Growth Of The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are focusing on obtaining regulatory approvals to enhance the credibility of their products, expand their market presence, and improve patient outcomes. Regulatory approvals refer to the official authorization of health authorities, confirming that a medical product, treatment, or technology meets safety, efficacy, and quality standards for public use. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received the Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test uses next-generation sequencing (NGS) technology to identify genetic mutations in cancer cells, enabling clinicians to select the most suitable treatments based on individual biomarkers. This approval marks a significant advancement in precision oncology, aiming to improve the speed and accuracy of treatment selection for cancer patients, ultimately enhancing personalized care.

Which Global Market Leaders Are Shaping The Future Of The Personalized Medicine Biomarkers Sector?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Personalized Medicine Biomarkers Market?

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Personalized Medicine Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2025, By The Business Research Company

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795